Allergan shareholder Paulson & Co is said to be urging the Botox maker to merge with specialty pharmaceutical company Shire. Photo: Eric Luke/The Irish Times

Allergan shareholder Paulson & Co is said to be urging the Botox maker to merge with specialty pharmaceutical company Shire as an alternative to (...)

The head offices of Valeant Pharmaceuticals International in Quebec. The ISS report comes as Allergan’s largest shareholder, hedge fund Pershing Square Capital Management, is urging the Botox maker to sell itself to Valeant. Photograph: Reuters/Christinne Muschi

Prominent investor shareholder advisory firm ISS called on Allergan to give its shareholders a chance to vote on any large, buyout-blocking acquisitio(...)

Pfizer has yet to formally put a value on the Actavis bid as it says no actual offer has been made, but it does make for a complicated chain all the same.

Keeping track of the merry-go-round that is pharma M&A is quite a challenge. It’s not all down to corporate inversion – that bête noir of US polit(...)

Billionaire investor William Ackman. Photograph: Scott Eells/Bloomberg

A few months ago an innovative partnership between Valeant Pharmaceuticals and billionaire investor William Ackman to buy Botox maker Allergan look(...)

Hasbro lost 3.3 per cent to $51.46. The toys and game maker reported second-quarter revenue that fell short of estimates. Photograph: Reuters

Shares fell across the globe as fighting erupted in eastern Ukraine, the first major eruption of violence there since a Malaysian airliner was shot do(...)

Allergan chief executive David Pyott. Allergan said the cost reductions, which are part of its efforts to convince investors that it is a better value as a stand-alone company, would help it deliver annual earnings growth of more than 20 per cent between 2014 and 2019.

Botox maker Allergan, which is fighting off a hostile bid from Valeant Pharmaceuticals, today announced 1,500 jobs cuts as part of a $475 million rest(...)

Dublin-headquartered Shire has been domiciled in Ireland for tax purposes since 2008

CHARLIE TAYLORAfter four unsuccessful bids, biopharmaceutical giant AbbVie has succeeded in acquiring peer Shire after upping its offer at the weekend(...)

The Food and Drug Administration approved Allergan’s Ozurdex, a drug for diabetic macular edema, which can cause vision loss and eventual blindness in people with diabetes, according to a regulatory filing today.

Allergan, the drugmaker resisting a takeover by Valeant Pharmaceuticals International , won US approval for a treatment of vision loss in diabetics a(...)

Shire shareholders deserve a higher price than US drugmaker AbbVie is offering, given the company’s growth prospects, Shire’s chief executive officer (...)

The battle between Valeant Pharmaceuticals and its latest target, Allergan, has thrown a harsh light on some of the tactics employed by investment banks pursuing lucrative advisory contracts. Photograph: Eric Luke

The life sciences sector is awash with M&A activity this year with one proposed megadeal swiftly following another. The frenetic activity is not c(...)